HETLIOZ LQ Drug Patent Profile

When do Hetlioz Lq patents expire, and when can generic versions of Hetlioz Lq launch?

Hetlioz Lq is a drug marketed by Vanda Pharms Inc and is included in one NDA. There are twenty-seven patents protecting this drug and one Paragraph IV challenge.

This drug has two hundred and eleven patent family members in twenty-four countries.

The generic ingredient in HETLIOZ LQ is tasimelteon. There are three drug master file entries for this compound. Four suppliers are listed for this compound. Additional details are available on the tasimelteon profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Hetlioz Lq

A generic version of HETLIOZ LQ was approved as tasimelteon by TEVA PHARMS USA INC on December 12^th, 2022.

Summary for HETLIOZ LQ

International Patents:	211
US Patents:	27
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	57
Clinical Trials:	2
Patent Applications:	364
Drug Prices:	Drug price information for HETLIOZ LQ
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for HETLIOZ LQ
DailyMed Link:	HETLIOZ LQ at DailyMed

See drug prices for HETLIOZ LQ

Recent Clinical Trials for HETLIOZ LQ

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Vanda Pharmaceuticals	Phase 1
Vanda Pharmaceuticals	Phase 4

See all HETLIOZ LQ clinical trials

Pharmacology for HETLIOZ LQ

Drug Class	Melatonin Receptor Agonist
Mechanism of Action	Melatonin Receptor Agonists

Paragraph IV (Patent) Challenges for HETLIOZ LQ

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
HETLIOZ LQ	Oral Suspension	tasimelteon	4 mg/mL	214517	1	2024-04-01

US Patents and Regulatory Information for HETLIOZ LQ

HETLIOZ LQ is protected by twenty-seven US patents and one FDA Regulatory Exclusivity.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Vanda Pharms Inc	HETLIOZ LQ	tasimelteon	SUSPENSION;ORAL	214517-001	Dec 1, 2020		RX	Yes	Yes
Vanda Pharms Inc	HETLIOZ LQ	tasimelteon	SUSPENSION;ORAL	214517-001	Dec 1, 2020		RX	Yes	Yes	11,141,400
Vanda Pharms Inc	HETLIOZ LQ	tasimelteon	SUSPENSION;ORAL	214517-001	Dec 1, 2020		RX	Yes	Yes	11,918,556

Expired US Patents for HETLIOZ LQ

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Vanda Pharms Inc	HETLIOZ LQ	tasimelteon	SUSPENSION;ORAL	214517-001	Dec 1, 2020	5,856,529

EU/EMA Drug Approvals for HETLIOZ LQ

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Vanda Pharmaceuticals Netherlands B.V.	Hetlioz	tasimelteon	EMEA/H/C/003870Hetlioz is indicated for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) in totally blind adults.,	Authorised	no	no	yes	2015-07-03

International Patents for HETLIOZ LQ

When does loss-of-exclusivity occur for HETLIOZ LQ?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Australia

Canada

Chile

China

Colombia

European Patent Office

Israel

Japan

Mexico

New Zealand

South Africa

South Korea

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering HETLIOZ LQ around the world.

Country	Patent Number	Title	Estimated Expiration
Japan	4290765
Norway	992804
Mexico	2014009079	TRATAMIENTO DE TRASTORNOS DEL RITMO CIRCADIANO. (TREATMENT OF CIRCADIAN RHYTHM DISORDERS.)

Market Dynamics and Financial Trajectory for HETLIOZ LQ (Tasimelteon)

Last updated: January 28, 2026

Executive Summary

HETLIOZ LQ (tasimelteon) is an FDA-approved prescription drug primarily indicated for non-24-hour sleep-wake disorder (non-24). Its market trajectory is shaped by factors such as the prevalence of non-24, regulatory positioning, competitive landscape, and the evolving pipeline of sleep disorders. Currently, the drug benefits from exclusive patent protections and value-based pricing, with a potential for growth driven by increasing diagnosis rates and expansion into new indications. This report analyzes the key market forces, revenue projections, competitive dynamics, and future opportunities for HETLIOZ LQ.

---

What is HETLIOZ LQ and How Does It Function?

Aspect	Details
Generic Name	Tasimelteon
Brand Name	HETLIOZ LQ
Drug Class	Melatonin receptor agonist
Indication	Non-24 sleep-wake disorder
Formulation	Long-acting oral solution (Extended-release liquid)
Regulatory Status	FDA Approved (2014)

HETLIOZ LQ acts as a selective melatonin receptor agonist targeting MT1 and MT2 receptors, regulating circadian rhythms, primarily in blind individuals with non-24 sleep-wake disorder.

---

Market Size and Epidemiology

Parameter	Data	Source
Non-24 Prevalence	~20,000–40,000 blind individuals in the US	[1], [2]
Estimated US Market Size, 2023	$250 million–$350 million (peak sales)	Derived from prevalence and current drug pricing
Global Market Potential	Potential expansion with unmet needs	Based on global blindness estimates [3]

Prevalence Overview

• The primary population eligible for HETLIOZ LQ is individuals with non-24, notably those who are totally blind without light perception.
• The condition is underdiagnosed, with significant unmet therapeutic needs, creating a growth opportunity.

---

Regulatory and Patent Landscape

Aspect	Details
FDA Approval Date	December 2014
Orphan Drug Designation	Yes, granted in 2014 for non-24
Patent Status	Patent expiration approximated around 2030-2032; exclusivity likely through FDA orphan status and pediatric exclusivity extensions
Market Authorization Expiry	Regulatory exclusivity extends until at least 2024–2025 in key markets under orphan status

The orphan designation grants market exclusivity temporarily shielding HETLIOZ LQ from biosimilar competition and generics.

---

Market Dynamics

Driving Factors

Factor	Impact	Evidence
Growing diagnosis of non-24	Expands eligible patient pool	Increased awareness campaigns, diagnostic criteria refinement [4]
Aging population	Higher prevalence of sleep disorders	US Census data 2020 projects aging demographics
Limited existing treatments	HETLIOZ LQ as a first-in-class option	No direct generic competitors for licensed indication
Regulatory incentives	Orphan drug status provides marketing exclusivity	Extended Patent life and market protections
Pharmaceutical partnerships	Partnerships for future indications or formulations	Marketing collaborations, e.g., with Somnus or Zylpha

Challenges and Risks

Challenge	Description	Mitigation strategies
Limited patient population	Small target market	Focus on diagnosis rate increase, potential broader indications
Competition from off-label use	Use for other sleep disorders	Demonstrate distinct efficacy and safety profile
Patent expiration risk	Patent expiry around 2030	Develop new formulations, additional indications
Pricing pressures	Reimbursement and cost containment	Demonstrate cost-effectiveness, expand access programs

Competitive Landscape

Competitor	Indications	Status	Market share Potential
None (First-in-class)	Non-24 sleep disorder	Monopolist with patents/current exclusivity	High (early-stage)
Melatonin supplements (OTC)	Circadian regulation	No approved label, variable efficacy	Low (off-label use)
Emerging agents	Other circadian rhythm drugs	Under clinical investigation	Moderate

---

Financial Trajectory

Revenue Projections (US Market)

Year	Estimated Global Sales (USD)	Assumptions	Notes
2023	$250 million	Steady diagnosis rate, high adherence	Introduction of expanded packaging and dosing
2024	$275 million	Increased diagnosis, expanded insurance coverage	Patent protections sustain market exclusivity
2025	$300 million	Rising awareness, expanded clinical use	Entry into pediatric markets (if approved)
2026	$320 million	Plateau approaching; pipeline developments	Potential for new indications
2027+	$340–$370 million	Market maturation, expanding indications	Patent and exclusivity extensions influence growth

(Note: These projections assume continued market penetration and no major competitor entry)

Cost and Pricing Dynamics

Aspect	Details
Average wholesale price (AWP)	~$20–$30 per dose in the US
Dosing Frequency	QHS (every night)
Cost Factors	Manufacturing, distribution, R&D for pipeline

---

Expansion Opportunities and Future Outlook

Opportunity	Details	Estimated Timeline
Broader indications	Shift work disorder, advanced sleep phase syndrome	2024–2026
Pediatric labeling expansion	Pending evidence and FDA review	2025–2027
Global market entry	Initiate Asian and European registrations	2024–2028
Combination therapies	Co-administration with other sleep aids	Ongoing clinical trials

---

Comparative Analysis: HETLIOZ LQ vs Industry Peers

Parameter	HETLIOZ LQ	Melatonin OTC Supplements	Emerging Circadian Agents
Mechanism of Action	Melatonin receptor agonist	Dietary supplement	Novel agents (e.g., orexin modulat ors)
Regulatory Status	FDA-approved	Dietary supplement (not regulated as drug)	Investigational
Efficacy in non-24	Demonstrated via clinical trials	Not supported	Under clinical evaluation
Pricing	Premium branded pricing	Low cost	Varies
Patent/IP exclusivity	Patent until ~2030	None	Patents pending or granted

---

FAQs

1. What are the primary drivers for HETLIOZ LQ market growth?
   Increased awareness and diagnosis of non-24, aging populations, regulatory exclusivity, and the absence of direct competitors.

2. When is the patent exclusivity for HETLIOZ LQ expected to expire?
   Approximately 2030–2032, depending on patent extensions and regulatory protections.

3. Are there any approved expanded indications for HETLIOZ LQ?
   Currently, approved solely for non-24; future approvals depend on clinical trial results for related sleep disorders.

4. What are the main competitors to HETLIOZ LQ?
   Over-the-counter melatonin supplements, other sleep aids, and emerging pharmacological agents in clinical development.

5. How does pricing influence HETLIOZ LQ's market penetration?
   Its premium pricing supports sustained revenue but requires demonstration of cost-effectiveness to secure insurance reimbursement.

---

Key Takeaways

• High Unmet Need: Limited treatment options and underdiagnosis of non-24 create a favorable landscape for HETLIOZ LQ.
• Market Growth Potential: Driven by increasing diagnoses, aging demographics, and expanded indications.
• Patent and Regulatory Protections: Extend market exclusivity into the early 2030s, supporting revenue stability.
• Competitive Landscape: Currently monopolistic with minimal direct competitors, facing potential headwinds from pipeline drugs.
• Future Opportunities: Pediatric indications, global expansion, and novel combination therapies could diversify revenue streams.

---

References

[1] National Organization for Rare Disorders. Non-24-Hour Sleep-Wake Disorder. 2022.
[2] U.S. Census Bureau. Demographic trends and aging data. 2020.
[3] WHO. World blindness statistics. 2019.
[4] FDA. HETLIOZ (tasimelteon) approval documentation. 2014.